실적 발표 분석으로 건너뛰기
← 피드로 돌아가기
EW FY2026 Q2 RAISED

Edwards Lifesciences Corporation 실적 발표

Jul 23, 2026 · 13:00 ET Bernard ZovighianDaveen ChopraDoretta Mistras
Buzzberg 분석

Full-year sales guidance raised to 10-11%

Edwards Lifesciences reported a strong Q2 2026 beat, raised full-year guidance across TAVR, TMTT, and total company, and maintained EPS outlook despite tax headwinds. Management highlighted sustained market share gains, robust TMTT portfolio growth (Pascal, Evoque, Sapien M3), and upcoming catalysts including Progress trial data and US NCD finalization. Total company revenue $1.74B (+12.5% y/y) beat expectations; TAVR $1.3B (+10.5%), TMTT $195.9M (+44.8%).

Buzzberg 분석 Full-year sales guidance raised to 10-11% Edwards Lifesciences reported a strong Q2 2026 beat, raised full-year guidance across TAVR, TMTT, and total company, and maintained EPS outlook despite tax headwinds. Management highlighted sustained market share gains, robust TMTT portfolio growth (Pascal, Evoque, Sapien M3), and upcoming catalysts including Progress trial data and US NCD finalization. Total company revenue $1.74B (+12.5% y/y) beat expectations; TAVR $1.3B (+10.5%), TMTT $195.9M (+44.8%). 전체 분석 보기분석 접기

Edwards Lifesciences reported a strong Q2 2026 beat, raised full-year guidance across TAVR, TMTT, and total company, and maintained EPS outlook despite tax headwinds. Management highlighted sustained market share gains, robust TMTT portfolio growth (Pascal, Evoque, Sapien M3), and upcoming catalysts including Progress trial data and US NCD finalization. Total company revenue $1.74B (+12.5% y/y) beat expectations; TAVR $1.3B (+10.5%), TMTT $195.9M (+44.8%).

  • FY2026 total revenue guidance raised to 10-11% growth ($6.6-6.9B); TAVR to 8-9% ($4.75-5B); TMTT to $760-780M.
  • Adjusted EPS guidance maintained at $2.95-$3.05 despite tax headwinds (higher effective rate).
  • Q3 2026 guided to $1.63-1.71B revenue and $0.71-0.77 EPS, reflecting higher prior-year comps.
TAVR revenue $1.3B +8% QoQ
TMTT revenue $0.1959B +13% QoQ
Revenue $1.741B +6% QoQ
EPS $0.78 +0% QoQ

이번 분기에 달라진 점

01
Guidance

Full-year sales guidance raised to 10-11%

Guidance · revenue to $6.75B

02
Demand

TMTT revenue grew 44.8% year-over-year

Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.

03
Demand

TAVR global sales up 10.5% to $1.3B

TMTT revenue grew 44.8% year-over-year. Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.

04
Demand

Growth benefited from competitor exit in Q2 2025

TMTT revenue grew 44.8% year-over-year. Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.

수요 및 자본지출

수요

수주 및 전환

TMTT revenue grew 44.8% year-over-year. Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.

자본지출

투자 및 생산능력

Management stated that their highest capital allocation priority is investing in organic growth and strengthening the manufacturing network, with ongoing investment in the business supporting operating margin expansion.

톤 · confident

Management expressed strong confidence driven by better-than-expected Q2 results, raised full-year guidance, and reiterated long-term growth targets, reflecting a notably upbeat tone.

향후 가이던스

RaisedGuidance · revenue to $6.75B
지표기간범위중간값상태
EPSFY2026$2.95–$3.05$3.00MAINTAINED
EPSFY2026 Q3$0.71–$0.77$0.74GUIDED
RevenueFY2026$6.6B–$6.9B$6.75BRAISED
RevenueTAVRFY2026$4.75B–$5B$4.875BRAISED
RevenueTMTTFY2026$0.76B–$0.78B$0.77BRAISED
RevenueFY2026 Q3$1.63B–$1.71B$1.67BGUIDED

가이던스 신뢰도

6 / 6달성 또는 상회
제시 시점지표목표 기간가이던스실제결과
FY2026 Q1EPSFY2026 Q2$0.70–$0.76$0.78Met / beat
FY2026 Q1RevenueFY2026 Q2$1.66B–$1.74B$1.741BMet / beat
FY2025 Q4EPSFY2026 Q1$0.70–$0.76$0.78Met / beat
FY2025 Q4RevenueFY2026 Q1$1.55B–$1.63B$1.6486BMet / beat
FY2025 Q3EPSFY2025 Q4$0.58–$0.64$0.58Met / beat
FY2025 Q3RevenueFY2025 Q4$1.51B–$1.59B$1.5696BMet / beat